“an osteoanabolic dental GEL formulation and preparation method thereof”

IN605240BActive Publication Date: 2026-10-07DR SUREKHA RATHOD +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202421072091
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-09-24
Publication Date
2026-10-07

AI Technical Summary

Technical Problem

Current treatments for periodontitis, such as systemic antibiotics and surgical procedures, can be irritating and non-compliant, with limited effectiveness in preventing recurrence, highlighting the need for a localized and sustained osteoanabolic therapy that promotes bone regeneration and oral hygiene.

Method used

A thermosensitive in-situ dental gel formulation combining teriparatide, vitamin D3, and beta-tricalcium phosphate, with poloxamer as a gelling agent, preservatives like methyl and propyl paraben, and distilled water, providing controlled and sustained drug delivery directly to periodontal pockets.

Benefits of technology

The formulation enhances bone regeneration, reduces systemic side effects, improves patient compliance, and offers a convenient treatment regimen by ensuring prolonged drug release and precise delivery to the affected area, effectively addressing periodontitis and supporting tissue regeneration.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

ABSTRACT “AN OSTEOANABOLIC DENTAL GEL FORMULATION AND PREPARATION METHOD THEREOF” The present invention in general relates to an osteoanabolic dental gel formulation. The dental gel comprises of teriparatide, vitamin D3 and beta-tricalcium phosphate along with pharmaceutically acceptable inert excipients. The invention further provides process for preparation of an osteoanabolic dental gel formulation.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF INVENTIONThe present invention in general relates to an osteoanabolic dental gelformulation.The dental gel comprises teriparatide, vitamin D3 and beta-tricalciumphosphate along with pharmaceutically acceptable inert excipients. The inventionfurther provides method for preparation of an osteoanabolic dental gelformulation.BACKGROUND OF INVENTIONOsteoanabolic agents are drugs that stimulate bone formation bypromoting the activity of osteoblasts, the cells responsible for bone synthesis.Unlike antiresorptive agents that merely slow bone loss, osteoanabolics activelyincrease bone mass, density, and strength. These agents, such as teriparatide (arecombinant form of parathyroid hormone), are commonly used to treatconditions like osteoporosis, where bone density is compromised. By stimulatingnew bone formation, they improve the structural integrity of the skeletal system,making them crucial in managing bone degenerative diseases.The role of osteoanabolic agents can extend beyond conditions likeosteoporosis and into dental and periodontal health. Periodontitis, a chronicinflammatory disease affecting the gums and supporting bone structures, poses asubstantial threat to oral health. It is characterized by the progressive destructionof tooth-supporting structures caused by bacterial biofilms. When oral hygiene isinadequate, plaque hardens into tartar, irritating the gums and progressing togingivitis. Untreated gingivitis can escalate into periodontitis, characterized byinflammation extending below the gumline, resulting in bone and tissuedestruction.Individuals with periodontitis may experience symptoms such as swollen,red, or tender gums, bleeding during brushing or flossing, persistent bad breath,loose teeth, tooth sensitivity, and changes in bite alignment. Several factorscontribute to the development of periodontitis, including poor oral hygiene,smoking, diabetes, hormonal fluctuations, certain medications, and geneticpredisposition.Preventive measures emphasize rigorous oral hygiene practices,comprising regular brushing and flossing, combined with consistent dentalcheckups and cleanings. Treatment modalities vary based on disease severity,ranging from non-surgical scaling and root planning to surgical interventions inadvanced cases. Early detection and comprehensive treatment are pivotal inmitigating disease progression and preserving oral health.Systemic antibiotic drugs, surgical procedures, and mechanical cleaningof the tooth surfaces (scaling and root planning) are traditional therapies forperiodontitis. These treatments can be beneficial, but they can also be irritatingfor the patient, necessitate repeated dental appointments, and not necessarilyprevent the illness from recurring. Local drug delivery is more beneficial thansystemic administration due to direct access to target disease, improvement ofpatient compliance, avoidance of gastrointestinal tract (GIT) related issues,bypass of first pass metabolism by the liver, thereby enhanced therapeuticefficacy of the drug.An osteoanabolic gel formulation refers to a topical or transdermal geldesigned to stimulate bone formation and increase bone mass. These gelscontain active ingredients like growth factors and bone morphogenetic proteinsthat stimulate bone formation. They are often used to treat fractures,osteoporosis, and dental issues. The gel base provides a controlled release ofthese ingredients, allowing for targeted delivery to the affected area. Thisinnovative approach offers a convenient and effective way to enhance bonehealing and regeneration.Thermosensitive in-situ gels represent a promising advancement in localtherapy for periodontitis. These innovative formulations exist as liquids at roomtemperature, allowing for easy injection into the periodontal pockets. Uponcontact with the body's warmer temperature, they undergo a transformation into agel, forming a localized depot for drug delivery.This unique property offers several advantages. The gel's ability to adhereto the periodontal pocket walls ensures prolonged drug release, maximizingtherapeutic efficacy. Secondly, the in-situ formation allows for precise drugdelivery directly to the affected area, minimizing systemic side effects.Additionally, the gel's sustained release profile often reduces the frequency ofadministration, improving patient compliance.Furthermore, these gels provide flexibility in drug combination, allowingfor the incorporation of multiple therapeutic agents to address different facets ofperiodontitis. The sustained release property often translates to reduced dosingfrequency, making the treatment regimen more convenient for patients.Thermosensitive in-situ gels undoubtedly hold significant promise in themanagement of periodontitis.An article entitled, 'Teriparatide and Osseous Regeneration in the OralCavity' by Jill D. Bashutsk in N Engl J Med. 2010 discloses conducted study onchronic periodontitis patients polymeric scaffold with bioactives that promotesperiodontal tissue regeneration, showing theraupectic potential for localizedbone defects in the jaw. An article entitled, 'Short-term Teriparatide Delivery and Osseointegration: AClinical Feasibility Study U. Kuchler in Journal of Dental Research 2011 disclosesteriparatide injection in implant surgery and concluded that osseointegration oftitanium study implants in individuals treated with teriparatide. An article entitled, 'Systemic Teriparatide Administration Promotes OsseousRegeneration of an Intrabony Defect: A Case Report' by Jill d. Bashutski, Janet s.Kinney in Journal of Periodontology 2017 conducted a study on intra-bony defecttreated with systemic administration of 20 ug of oral vitamin D and calciumsupplements for 6 weeks showed that potential regeneration for the treatment ofintra-bony defects. There is still need for an osteoanabolic dental gel formulation that leveragesthe effect of teriparatide, vitamin D3 and beta-tricalcium phosphate in a singleformulation to effectively combat periodontitis and address the critical need for aneffective adjunctive treatment for periodontitis, ultimately benefiting patients bypromoting better oral hygiene, patient compliance preventing diseaseprogression, and supporting tissue regeneration.OBJECTS OF THE INVENTIONMain object of the present invention is to provide an osteoanabolic dentalgel formulation intended for periodontitis.Another object of the present invention is to provide an osteoanabolicdental gel formulation comprising teriparatide, vitamin D3 and beta-tricalciumphosphate.Another object of the present invention is to provide an osteoanabolicdental gel formulation in the form of thermosensitive in-situ gel.Yet another object of the present invention is to provide a process forpreparation of an osteoanabolic dental gel formulation comprising teriparatide inthe form of thermosensitive in-situ gel.SUMMARY OF THE INVENTIONIn an embodiment, the present invention relates to an osteoanabolicdental gel formulation comprising,a) Teriparatide;b) Vitamin D3;c) Beta-tricalcium phosphate; andd) Pharmaceutically acceptable inert excipients.In an aspect of the embodiment, the dental gel is in the form ofthermosensitive in-situ gel.In an aspect of the embodiment, the pharmaceutically acceptable inertexcipients are gelling agent, preservatives and solvent.In another aspect of the embodiment, the gelling agent is poloxamer.In another aspect of the embodiment, the preservatives are methyl andpropyl paraben.In another aspect of the embodiment, the solvent is distilled water.In another embodiment, an osteoanabolic dental gel formulationcomprising,a) 0.0025% w / v of Teriparatide;b) 0.002% w / v of Vitamin D3;c) 10% w / v of Beta-tricalcium phosphate;d) 20% w / v of Poloxamer;e) 5% w / w of Ethanol;f) 0.18% w / v of Methyl paraben;g) 0.02% w / v of Propyl paraben; andh) Distilled water;wherein the percentages are with respect to total weight of theformulation.In another embodiment, the present invention relates to a process for thepreparation of an osteoanabolic dental gel formulation comprises the steps of;a) Dissolving poloxamer in distilled water to form a gel base;b) Adding vitamin D3, ethanol, methyl paraben and propyl paraben tothe gel base to form solution;c) Adding beta-tricalcium phosphate and teriparatide to the solutionand making up the volume using distilled water to obtain finalformulation.BRIEF DESCRIPTION OF THE DRAWINGS:The accompanying drawings are included to provide a further understanding ofthe present invention and are incorporated in and constitute a part of thisspecification. The drawings illustrate exemplary embodiments of the presentinvention and, together with the description, serve to explain the principles of thepresent disclosure.- Figure 1 illustrates zone of inhibition exhibited after 24 hours byDoxycycline, Formulation (In situ teriparatide gel), gel base and Water forinjection (WFI) against bacterial strain Escherichia coli.- Figure 2 illustrates zone of inhibition exhibited after 24 hours byDoxycycline, Formulation (In situ teriparatide gel), gel base and Water forinjection (WFI) against bacterial strain Staphylococcus aureus.DETAILED DESCRIPTION OF THE INVENTION:The present invention is all about an osteoanabolic dental gel formulationcomprising,a) Teriparatide;b) Vitamin D3;c) Beta-tricalcium phosphate; andd) Pharmaceutically acceptable inert excipients.Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill in theart to which the invention pertains.The term "comprising", which is synonymous with "including", "containing", or"characterized by" here is defined as being inclusive or open-ended, and doesnot exclude additional, unrecited elements or method steps, unless the contextclearly requires otherwise.The term "a" and "an" refers to one or to more than one (i.e., to at leastone) of the grammatical object of the article. The information provided in thisdocument, and particularly the specific details of the described exemplaryaspects, is provided primarily for clearness of understanding and no unnecessarylimitations are to be understood from there.As used herein, the term "about" means that the numerical value isapproximate and small variations would not significantly affect the practice of thedisclosed embodiments. Where a numerical limitation is used, unless indicatedotherwise by the context, "about" means the numerical value can vary by ±10%and remain within the scope of the disclosed embodiments.The term "osteoanabolic" refers to a process of building up bone tissue,often by promoting the activity of bone-forming cells called osteoblasts.The term "Dental gel formulation" is a specialized topical preparationdesigned for application in the oral cavity, particularly on the gums and teeth. It isused to deliver active ingredients directly to the oral tissues for the treatment andprevention of various dental conditions such as gum disease, tooth decay, andoral infections. Dental gels are formulated to adhere to the mucous membranesand teeth, ensuring prolonged contact with the active ingredients for effectivetherapeutic action.The term "pharmaceutically acceptable inert excipients", denotes any ofthe components of a cosmetic formulation other than the active and which areapproved by regulatory authorities or are generally 'regarded as safe' for humanuse. A combination of excipients may also be used. The amount of excipient(s)employed will depend upon how much active agent is to be used. One excipientcan perform more than one function.Although the invention has been described with reference to specificembodiments, this description is not meant to be construed in a limiting sense.Various modifications of the disclosed embodiments, as well as alternateembodiments of the invention, will become apparent to persons skilled in the artupon reference to the description of the invention. It is therefore contemplatedthat such modifications can be made without departing from the spirit or scope ofthe present invention as defined.Main embodiment of the present invention relates to an osteoanabolicdental gel formulation comprising,a) Teriparatide;b) Vitamin D3;c) Beta-tricalcium phosphate; andd) Pharmaceutically acceptable inert excipients.Teriparatide, a synthetic form of parathyroid hormone, has emerged as apromising adjunct therapy for periodontitis. Primarily known for its role in treatingosteoporosis due to its bone-building properties, its application in periodontalregeneration is gaining traction. The underlying principle is the ability ofteriparatide to stimulate bone formation. Periodontitis is characterized bysignificant bone loss around the teeth, this anabolic effect can be harnessed topromote alveolar bone regeneration.Vitamin D3 has emerged as a potential player in the management ofperiodontitis. This fat-soluble vitamin is primarily known for its role in calciumabsorption and bone health. Vitamin D's potential benefits for periodontitis stemfrom its anti-inflammatory and immunomodulatory properties. It helps regulate theimmune response, which is crucial in fighting the bacterial infection that causesperiodontitis. Additionally, vitamin D supports bone health, and as periodontitisleads to bone loss around the teeth, maintaining optimal vitamin D levels mighthelp slow down this process.Beta-tricalcium phosphate (β-TCP) is a synthetic bone graft materialcommonly employed in the treatment of periodontitis. Its role is primarily focusedon regenerating bone lost due to the disease. This biocompatible ceramicmaterial serves as a scaffold, encouraging the growth and integration of newbone cells. As the body gradually absorbs the β-TCP, it is replaced by newlyformed bone tissue. One of the primary advantages of β-TCP is itsbiocompatibility, meaning it is well-tolerated by the body. It also possessesosteoconductive properties, providing a suitable surface for bone cells to attachand proliferate.In another aspect of the embodiment, the dental gel is in the form ofthermosensitive in-situ gel.In another aspect of the embodiment, the pharmaceutically acceptableinert excipients are gelling agent, preservatives and solvent.The formulation includes gelling agent. A gelling agent is a substance thatimparts a gel-like consistency to a liquid. These substances transform liquids intosemi-solid preparations like gels, creams, and ointments. By creating a threedimensional network within the liquid, gelling agents provide the formulation withits characteristic texture and consistency. This structure also plays a crucial rolein controlling the release rate of active ingredients, allowing for sustained orcontrolled drug delivery.In another aspect of the embodiment, the gelling agent is poloxamer in aconcentration of 20% w / v.Poloxamers are a class of polymers widely employed as gelling agents inthe formulation of thermosensitive in-situ gels. These unique polymers possess atriblock structure comprising hydrophilic and hydrophobic segments. At lowertemperatures, they exist as fluid solutions, facilitating easy administration. Uponexposure to body temperature, a remarkable transformation occurs as thepolymer chains associate to form a gel-like structure. This in-situ gelationproperty offers several advantages, including sustained drug release, improveddrug bioavailability, and enhanced residence time at the target site.Preservatives are substances added to pharmaceutical formulations toprevent microbial growth and extend product shelf life. These substances act byinterfering with the metabolic processes of microorganisms, preventing theirproliferation and contamination of the product. Common preservative typesinclude parabens, quaternary ammonium compounds, alcohols, and organicacids.In another aspect of the embodiment, the preservatives are methylparaben and propyl paraben in a concentration of 0.18% w / v and 0.02% w / vrespectively.Methyl paraben and Propyl paraben, commonly referred to as parabens,are widely employed as preservatives in pharmaceutical formulations. Thesesynthetic compounds exhibit potent antimicrobial properties, effectively inhibitingthe growth of a broad spectrum of microorganisms. Their efficacy is attributed totheir ability to disrupt microbial cell membranes.Solvents are essential components in pharmaceutical formulations,serving as the liquid medium that dissolves and homogenizes variousingredients. They play a pivotal role in ensuring the solubility, stability, andbioavailability of the active pharmaceutical ingredient (API).In another aspect of the embodiment, the solvent is distilled water.Distilled water is a commonly used solvent in pharmaceutical formulationsdue to its purity and lack of contaminants. It serves as a universal solvent formany hydrophilic compounds and is employed in a wide range of products,including injections, oral solutions, and topical preparations. It is a valuablesolvent in pharmaceutical manufacturing, offering a cost-effective and widelyavailable option for many formulations.In another embodiment, an osteoanabolic dental gel formulationcomprising,a) 0.0025% w / v of Teriparatide;b) 0.002% w / v of Vitamin D3;c) 10% w / v of Beta-tricalcium phosphate;d) 20% w / v of Poloxamer;e) 5% w / w of Ethanol;f) 0.18% w / v of Methyl paraben;g) 0.02% w / v of Propyl paraben; andh) Distilled water.wherein the percentages are with respect to total weight of theformulation.In another aspect of embodiment, the formulation exhibits antibacterialactivity.In another aspect of embodiment, the viscosity of formulation is 32430centipoises.In another embodiment, the present invention relates to a process forpreparation of an osteoanabolic dental gel formulation comprising the steps of;a) Dissolving poloxamer in distilled water to form a gel base;b) Adding vitamin D3, ethanol, methyl paraben and propyl paraben to thegel base to form solution;c) Adding beta-tricalcium phosphate and teriparatide to the solution andmaking up the volume using distilled water to obtain final formulation.In another aspect of embodiment, the dental gel is prepared using coldmethod or thermal gelation method.EXAMPLESExample 1: An osteoanabolic dental gel formulation according to inventionTable no.1 - An osteoanabolic dental gel formulation according to inventionManufacturing Process of an osteoanabolic dental gel formulation -a) Poloxamer was dissolved in distilled water while maintaining the coldconditions to form a gel base;b) The gel base was sterilized in an autoclave and 5ml of the gel base wastaken in a sterilized ambered coloured bottle;c) Vitamin D3, Ethanol, Methyl paraben and Propyl paraben were added inthe gel base to form solution;d) Beta-tricalcium phosphate and Teriparatide were added slowly to thesolution, and volume was made-up using distilled water to obtain anosteoanabolic dental gel formulation.Example 2: Characterization of an osteoanabolic dental gel formulation -- Physical appearance:The physical appearance of the formulation was checked visually for clarityagainst white and black backgrounds in light.Formulation F1 F2 F3Appearance Whitish Whitish WhitishColour White White WhiteOdour Characteristic Characteristic CharacteristicConsistency Smooth Smooth SmoothClarity Good Good GoodTable no. 2 - Physical evaluation of an osteoanabolic dental gel- Determination of pH:The pH value of the prepared osteoanabolic dental gel was measured using adigital pH meter.Table no. 3 - pH of an osteoanabolic dental gel- Determination of Viscosity:Viscosity is an expression of the resistance of a fluid to flow. Viscosity of gels wasdetermined by using Brookfield Viscometer.Viscosity (cp) (Spindle no. 64)Table no. 4 - Viscosity of an osteoanabolic dental gel- Gelation Temperature and Gelling Time:Gelation time refers to the amount of time it takes for a liquid or solution to solidifyinto a gel. Gelation temperature is the temperature at which the gelation processoccurs.Table no. 5 - Gelation temperature and gelling time of an osteoanabolic dentalgel- Syringeability Study:Syringeability refers to the ease with which a gel can be injected or drawn up intoa syringe.Table no. 6 - Syringeability Study of an osteoanabolic dental gel- Drug Content:Drug content refers to the amount of active pharmaceutical ingredient present in agel formulation. Drug content of batch F3 was evaluated, and it was found tocontain 90.64% of drug.- In-vitro Drug Release:In-vitro release refers to the process of studying how a drug or other substance isreleased from a gel under controlled laboratory conditions.Table no. 7 - In-vitro drug release of an osteoanabolic dental gel- Stability Studies:Stability studies for gels are a series of tests conducted to assess how the gel'sproperties change over time under various conditions. Stability studies werecarried out on gel formulation according to ICH guidelines.Table no.8 -Stability Studies of an osteoanabolic dental gel- Antibacterial Activity:The synthesized compounds tested against bacterial strains like gram-positive S.aureus and gram-negative E. coli. A 100 μl solution of test sample teriparatidecontaining gel and gel base without drug was added to the respective wells.Water for injection served as negative control and the standard antibacterial drugDoxycycline (100 μg / ml) were used as positive control. The activity wasdetermined by measuring the diameter of zone showing complete inhibition (mm).The growth inhibition was calculated with reference to the positive control. Referfigure 1 and 2.Table no.9 -Antibacterial activity of an osteoanabolic dental gel

Claims

1. An osteoanabolic dental gel formulation comprising, a) Teriparatide; b) Vitamin D3; c) Beta-tricalcium phosphate; and d) Pharmaceutically acceptable inert excipients.

2. The formulation as claimed in claim 1, wherein the dental gel is in the form of thermosensitive in-situ gel.

3. The formulation as claimed in claim 1, wherein the pharmaceutically acceptable inert excipients are gelling agent, preservatives and solvent.

4. The formulation as claimed in claim 3, wherein the gelling agent is poloxamer.

5. The formulation as claimed in claim 3, wherein the preservatives are methyl paraben and propyl paraben.

6. An osteoanabolic dental gel formulation comprising, a) 0.0025% w / v of Teriparatide; b) 0.002% w / v of Vitamin D3; c) 10% w / v of Beta-tricalcium phosphate; d) 20% w / v of Poloxamer; e) 5% w / w of Ethanol; f) 0.18% w / v of Methyl paraben; g) 0.02% w / v of Propyl paraben; and h) Distilled water; wherein the percentages are with respect to total weight of the formulation.

7. The formulation as claimed in claim 6, wherein the formulation exhibits antibacterial activity.

8. The formulation as claimed in claim 6, wherein the viscosity of formulation is 32430 centipoises.

9. A process for preparation of an osteoanabolic dental gel formulation comprises the steps of; a) Dissolving poloxamer in distilled water to form a gel base; b) Adding vitamin D3 , ethanol, methyl paraben and propyl paraben to the gel base to form solution; c) Adding beta-tricalcium phosphate and teriparatide to the solution and making up the volume using distilled water to obtain gel formulation.

10. The process as claimed in claim 9, wherein the dental gel is prepared using cold method or thermal gelation method.